Document Detail

A proposal of simple calculation (ERI calculator) to predict the early response to TNF-α blockers therapy in rheumatoid arthritis.
MedLine Citation:
PMID:  21110028     Owner:  NLM     Status:  MEDLINE    
Increasing evidence has been accumulated for treating rheumatoid arthritis (RA) with TNF-α blocking agents. The formulation and definition of an early indicator of patient's reactivity during therapy may be extremely simplified by a mathematical model of clinical response. We analyzed the most significant clinical and laboratory parameters of response of 35 homogeneous patients (30 women, 5 men mean age ± SD: 52.31 ± 12.30 years) treated with adalimumab 40 mg every 2 weeks associated with methotrexate (MTX) 10-15 mg/week and with a stable dosage of steroids for 30 weeks. The over time trend of the studied parameters showed a linear response, which has allowed the realization of a simple mathematical model. The formula derived from this mathematical model was then applied and therefore validated in a group of 121 patients previously treated with several anti-TNF-alpha agents for at least 6 months. We drafted a mathematical model (early response indicator, ERI) that, by using a simple calculation, allows us to identify a high percentage of responder patients after only 2 weeks of treatment. ERI identified a high percentage (88%) of patients responding after only 2 weeks, as was confirmed at weeks 30; the use of ERI calculation after 6 weeks increases the proportion of responding patients to 92% with a percentage of false negatives of only 12%. ERI could be a useful tool to early differentiate the responder from the non-responder patients.
Laura Bazzichi; Paolo Rossi; Camillo Giacomelli; Francesca De Feo; Francesca Bobbio-Pallavicini; Alessandra Rossi; Chiara Baldini; Arianna Consensi; Marica Doveri; Claudia Bonino; Maurizio Mazzantini; Alessandra Della Rossa; Carlomaurizio Montecucco; Stefano Bombardieri
Related Documents :
19834958 - Effect of allopurinol versus urate oxidase on methotrexate pharmacokinetics in children...
23100958 - Transfusion of neocytes concentrate/pooled neocytes in β-thalassemic patients.
23542158 - The relationship between γ-glutamyl transferase levels and the clinical outcomes in pa...
24260718 - Diabetic foot: surgical approach in emergency.
9419948 - Core decompression in treating ischemic necrosis of the femoral head.
22935938 - Direct thrombin inhibitors for management of heparin-induced thrombocytopenia in patien...
Publication Detail:
Type:  Clinical Trial; Journal Article     Date:  2010-11-26
Journal Detail:
Title:  Rheumatology international     Volume:  32     ISSN:  1437-160X     ISO Abbreviation:  Rheumatol. Int.     Publication Date:  2012 Feb 
Date Detail:
Created Date:  2012-01-24     Completed Date:  2012-10-15     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  8206885     Medline TA:  Rheumatol Int     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  349-56     Citation Subset:  IM    
Department of Internal Medicine, Division of Rheumatology, University of Pisa, Via Roma, 67, 56100 Pisa, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal, Humanized / administration & dosage*,  adverse effects
Antirheumatic Agents / administration & dosage*,  adverse effects
Arthritis, Rheumatoid / diagnosis,  drug therapy*
Middle Aged
Models, Immunological*
Predictive Value of Tests
Time Factors
Tumor Necrosis Factor-alpha / antagonists & inhibitors*,  metabolism
Reg. No./Substance:
0/Antibodies, Monoclonal, Humanized; 0/Antirheumatic Agents; 0/Tumor Necrosis Factor-alpha; FYS6T7F842/adalimumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effects of extracorporal shock wave therapy on symptomatic heel spurs: a correlation between clinica...
Next Document:  Increased male reproductive success in Ts65Dn "Down syndrome" mice.